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The Advance Notice of Proposed
Rulemaking (ANPRM)
or
74 Questions, But Who’s Counting?
Ivor A. Pritchard, Ph.D.
Senior Advisor to the Director
Office for Human Research Protections
Ivor.Pritchard@hhs.gov
September 26, 2011

“Human Subjects Research
Protections: Enhancing Protections
for Research Subjects and
Reducing Burden, Delay and
Ambiguity for Investigators”
(Federal Register July 26, 2011)

Office for Human
Research Protections
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Regulatory Jurisdiction
• “Research” “Quality Improvement” “Program”
etc.?
• Should all biospecimens research be covered?
[“Human Subject”?]
• Apply the regulations to all human subjects
research at domestic institutions receiving
Common Rule support?

3 levels of review,
depending on risk + X
Convened
IRB Review
Expedited Review

“Excused” or “Registered”

Convened IRB Review
• Should continuing review no longer be
required if the research is in the analysis or
follow-up phase?
• Should there be single IRB review of domestic
sites of multi-site studies?
• Should accountability requirements be set for
the site institutions and the single IRB?

Expedited Review
• Should there be single expedited review of domestic
sites of multi-site studies?
• Revise the list of categories, and revise them again
periodically?
• Presume that the identified research procedures are
minimal risk?
• If eligible, should the research receive expedited review
unless the reviewer refers it for a reason?
• Should any of the .111 criteria be omitted?
• Should continuing review occur only if and when it is
appropriate?

“Excused” or “Registered”
Research
• Registration Form Submitted
• Informed Consent (sometimes)
• Data Security and Information Protection
Standards applied
• Sometimes audited retrospectively
• May be referred for expedited or convened
IRB review, depending on …..[X]

Revising the scope of the existing exempt
categories for “excused” or “registered”
research
• Expand category .101(b)(2) by removing the
anonymity & risky response conditions for
research involving competent adults?
• Expand category .101(b)(4) by removing the
“existing” & anonymous recording conditions?
• Add a new category of benign interventions
research?
• Add other categories?

How to improve informed consent

Informed Consent
• How could the Informed Consent process be
improved?
• Should written consent generally be required
for research use of any biospecimens collected
for clinical or research purposes?
• Should “oral consent” be employed for some
studies, e.g. surveys with competent adults,
and, if so, how?

Informed Consent (cont.)
• Should investigators assess subjects’
understanding?
• Should the criteria for waiver of informed
consent be revised and clarified?
• Should the criteria for waiver of
documentation of informed consent be
revised?

Improving Informed Consent forms
• Identify appropriate specific content that must
be included?
• Identify content that may not be included?
• Identify how information should be presented?
• Limit the acceptable length of various
sections?
• Make standardized consent form template(s)
available?

Research with Biospecimens

Research with Biospecimens
• What should the requirements be for research
with specimens that already exist?
• Should secondary research with biospecimens
be “excused” from review unless there is a
waiver of informed consent or if individual
results will be returned to subjects?
• Should research on de-identified biospecimens
without consent or review be allowed?

Research with Biospecimens (cont.)
• What criteria should be used for waiver of
consent for future research on biospecimens?
• Should open-ended consent for future research
with bio-specimens be implemented?
• Should people be able to exclude certain types
of future research with their biospecimens?

Excused Research
Involving PreExisting Information
or Biospecimens

Identifiable info and
all biospecimens

Limited data set (as
defined in HIPAA
Rule)

Deidentified Info (as
defined in HIPAA
Rule)

Written IC req’d for
future research
w/material collected
for non-research?

Yes, which could be
obtained during initial
collection

No consent required

No consent required

IC for future research
w/material collected
for research?

Yes, usually at time of Yes (same rule as
“Identifiable info and
consent for initial
research (could be oral all biospecimens”)
for data)

Standardized data
protections?

Yes, Protections
include encryption,
authorized personnel,
breach notification,
audits

Yes (same rule as
“Identifiable info and
all biospecimens” +
prohibition on
reidentification)

Yes. Protection would
include prohibition on
reidentification

Registration of
research w/IRB or
research office?

Yes

Yes

No

Prior review by IRB
or research office?

No, unless PI plans to
re-contact subjects

No

No

Yes (same rule as
“Identifiable info and
all biospecimens”)
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Harmony/Uniformity

Harmony/Uniformity
• Should there be harmony with other regulations,
including Subparts B, C, D, HIPAA, FDA, etc.?
• Should we have a uniform set of Standards for
Data Security and Information Protection,
calibrated according to identifiability?
• Should there be uniformity of guidance from all
of the Common Rule agencies?
• Should there be uniformity of information
reported to the federal government?

ANPRM Comments due 10/26/11
Identify by docket ID number HHS-OPHS-2011-0005
• Federal eRulemaking Portal:
http://www.regulations.gov/
• Mail/Hand delivery/Courier [For paper, disk, or CDROM submissions] to: Jerry Menikoff, M.D., J.D.,
OHRP, 1101 Wootton Parkway, Suite 200, Rockville,
MD 20852.
Comments received, including any personal information,
will be posted without change to
http://www.regulations.gov/

